Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Davide Prandi Clear advanced filters

  • Mark Rubin, Francesca Demichelis and colleagues study the evolution of urothelial carcinomas by performing whole-exome sequencing of tumors collected from patients before and after chemotherapy. They find marked within-patient tumor heterogeneity and increased mutations involved in integrin signaling pathways and APOBEC-induced mutation signatures after treatment.

    • Bishoy M Faltas
    • Davide Prandi
    • Mark A Rubin
    Research
    Nature Genetics
    Volume: 48, P: 1490-1499

  • The differentiation of prostate adenocarcinoma to neuroendocrine prostate cancer (CRPC-NE) is a mechanism of resistance to androgen deprivation therapy. Here the authors show that SWI/SNF chromatin-remodeling complex is deregulated in CRPC-NE and that the complex interacts with different lineage specific factors throughout prostate cancer transdifferentiation.

    • Joanna Cyrta
    • Anke Augspach
    • Mark A. Rubin
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-16

  • While CRISPR-Cas9 is a powerful technology, it’sin vivoapplication can be limited by unwanted off-target editing events. Here the authors present SLiCES, a self-limiting Cas9 circuit to enhance editing by preventing residual nuclease activity.

    • Gianluca Petris
    • Antonio Casini
    • Anna Cereseto
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-9

  • Genome-wide DNA methylation analysis of metastatic biopsies from patients with castration-resistant prostate cancer reveals marked epigenetic differences between samples with adenocarcinoma and neuroendocrine histologies.

    • Himisha Beltran
    • Davide Prandi
    • Francesca Demichelis
    Research
    Nature Medicine
    Volume: 22, P: 298-305

  • There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.

    • Loredana Puca
    • Rohan Bareja
    • Himisha Beltran
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-10